PI change on the agenda

TGA issues safety reminder and advises of updates to infliximab product information Changes to the product information of Remicade (infliximab) have been flagged by the TGA in a recent newsletter, in which it also said there had been an increase in adverse event reports linked to lupus-like symptoms. In its December 2018 Medicines Safety Update,